E2F6 and glioblastoma: To date, no clinical trials have directly evaluated therapeutic targets identified through CRISPR-based genetic screening in GBM; although several candidate genes such as MAP4K4, E2F6, and UBE2N have demonstrated preclinical promise, their translation into clinical settings remains at an early stage, highlighting the need for further in vivo validation and tumor-specific delivery strategies.